Vaccine for HIV Using a Novel Mucosal Vector and Adjuvant

Stephen Kent and John Stambas of the University of Melbourne in Australia will develop and test an attenuated influenza virus vector with an adjuvant that stimulates natural killer cells. The goal of this approach is to induce robust immunity at mucosal surfaces to HIV, which is important in both prevention and control of infection.